Form 4: Halozyme CEO Helen Torley Trades Shares

Halozyme Therapeutics President and CEO Helen Torley executed a series of stock transactions on July 8, 2026, including the exercise of stock options and the sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Summary

• Helen Torley, President and CEO of Halozyme Therapeutics, Inc., engaged in stock transactions on July 8, 2026.
• These transactions included the exercise of stock options to acquire 1,923 shares of common stock at a price of $12.07 per share.
• Following the option exercise, Torley sold a total of 2,961 shares of common stock.
• The sales were executed at weighted average prices of $79.276 and $80.187 per share.
• All transactions were performed under a written trading plan adopted on March 21, 2025, in compliance with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• Torley's beneficial ownership of common stock following these transactions is reported as 767,780 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a significant number of shares being sold by the CEO, the transactions were conducted under a pre-established Rule 10b5-1 plan, mitigating concerns about opportunistic trading.

Positives

• Transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The CEO continues to hold a significant number of shares (767,780) after the reported transactions.

Negatives

• The CEO sold a substantial number of shares (2,961), which could be perceived negatively by the market, despite being part of a pre-planned strategy.
• The sale of shares at prices significantly higher than the option exercise price ($79.276/$80.187 vs. $12.07) represents a considerable realization of value for the executive.

Risks

• Potential for negative market perception due to the sale of a significant number of shares by a key executive, even if executed under a 10b5-1 plan.
• The weighted average sale prices indicate a range of selling prices, with the lower end of the range being $78.710 and the higher end $80.490, suggesting potential price volatility around the transaction dates.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions by an insider.

Management Comments

• The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
• The shares were sold at prices ranging from $78.710 to $79.700 (weighted average $79.276).
• The shares were sold at prices ranging from $79.710 to $80.490 (weighted average $80.187).
• The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. The execution of trades under a Rule 10b5-1 plan is a common practice for executives to diversify holdings or manage personal finances while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by the CEO as a signal, though the Rule 10b5-1 plan provides a mitigating context.
• Employees: May observe executive compensation and trading activities.
• Management: The transactions reflect the CEO's personal financial management and compensation realization.

Next Steps

• The reporting person will provide further details on share sales at specific prices upon request from the issuer, security holders, or the SEC staff.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Halozyme Therapeutics, HALO, Helen Torley, Executive Compensation, Beneficial Ownership